公开(公告)号：US20230157987A1

公开(公告)日：2023-05-25

申请号：US17917715

申请日：2021-04-09

申请人： Steven Robert Laviolette ,  Marta De Felice ,  Richard Rusiniak ,  Paul Ramsay

发明人： Steven Robert Laviolette ,  Marta De Felice ,  Richard Rusiniak ,  Paul Ramsay

IPC分类号： A61K31/202 ,  A61K31/05

CPC分类号： A61K31/202 ,  A61K31/05

摘要： The formulation includes CBD and a PPAR agonist. The PPAR agonist can be an omega-3 based PPAR agonist and more specifically can comprise substantially equal parts DHA and EPA.

公开(公告)号：US20210161856A1

公开(公告)日：2021-06-03

申请号：US17267003

申请日：2019-08-08

申请人： Steven Robert LAVIOLETTE ,  Marta DE FELICE ,  Richard RUSINIAK ,  Paul RAMSAY

发明人： Steven Robert LAVIOLETTE ,  Marta DE FELICE ,  Richard RUSINIAK ,  Paul RAMSAY

IPC分类号： A61K31/352 ,  A61P25/00 ,  A61K9/00 ,  A61K31/198

摘要： A method is for use with a treatment regime that includes the exposure of a patient to THC. The method comprises the step of administering Theanine to the patient. The Theanine can be L-Theanine. The treatment regime can involve a plurality of administrations of THC and Theanine can be administered with each administration of THC. The method of administration can be such that the peak bioavailability of THC occurs substantially contemporaneously with the peak bioavailability of Theanine. A consumer package can be adapted for carrying out the method.